PEG MGF

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, pegylated version of Mechano Growth Factor (MGF), an IGF-1Ec splice variant. Pegylation — the covalent attachment of polyethylene glycol (PEG) — increases molecular stability and significantly prolongs circulation time in experimental systems. This modification extends the peptide’s half-life from approximately 5–7 minutes to several hours or days in published research, enhancing exposure in laboratory models. Regulatory Status:
Not FDA-approved. Not intended for human administration, therapeutic use, or clinical applications. Mechanism of Action (Mechanistic descriptions based on published research models; NOT effects of this product.) Activates satellite cells (muscle stem cells) in response to mechanical stress or injury in preclinical studies. Acts via autocrine/paracrine–type signaling pathways rather than systemic endocrine mechanisms. Stimulates cellular proliferation, differentiation, and migration in skeletal muscle, cardiac tissue, cartilage, bone, and neural tissue. Pegylation shields the peptide from rapid enzymatic degradation while maintaining biological activity in in-vitro or in-vivo research systems. Tissue Specificity Skeletal Muscle: Investigated for involvement in muscle repair, hypertrophy signaling, and satellite-cell activation. Cardiac Tissue: Studied in relation to cardiomyocyte signaling, apoptosis pathways, and post-injury remodeling in experimental models. Bone & Cartilage: Associated with osteoblast proliferation and cartilage regeneration pathways. Neural Tissue: Examined in neuroprotection and motor-neuron survival models.